Turkish Journal of Medical Sciences
Volume 41

Number 1

Article 20

1-1-2011

Management of community-acquired acute bacterial cystitis in
Turkey
ÖMER COŞKUN
HAKAN ERDEM
ALİ AVCI

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
COŞKUN, ÖMER; ERDEM, HAKAN; and AVCI, ALİ (2011) "Management of community-acquired acute
bacterial cystitis in Turkey," Turkish Journal of Medical Sciences: Vol. 41: No. 1, Article 20. https://doi.org/
10.3906/sag-0908-158
Available at: https://journals.tubitak.gov.tr/medical/vol41/iss1/20

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Original Article

Turk J Med Sci
2011; 41 (1): 149-157
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-0908-158

Management of community-acquired acute bacterial
cystitis in Turkey
Ömer COŞKUN1, Hakan ERDEM2, Ali AVCI3

Aim: Community acquired acute bacterial cystitis (CA-ABC) is one of the most common infectious presentations in
the community. This paper aims to provide a rational approach in the management of CA-ABC based on local Turkish
data.
Materials and methods: The publications evaluating the microbiological data obtained from CA-ABC cases were
searched in both Turkish and international databases.
Results: Fosfomycin and nitrofurantain appear to be baseline antibiotics while the empirical use of trimethoprim
sulfamethoxazole, amoxicillin clavulanate, and first and second generation cephalosporins seems to be unreliable in
Turkey. Moreover, quinolones seem to be at the edge with resistance rates up to 20%. On the other hand, aminoglicosides,
third and fourth generation cephalosporins, and piperacillin-tazobactam look more trustworthy.
Conclusion: According to local Turkish data, caution is really indicated in rational antibiotic use in the community since
the traditional drugs used in the management of CA-ABC are being lost steadily.
Key words: Community-acquired, urinary, infection, Turkey

Türkiye'de toplum kökenli akut baktriyel sistit tedavisi
Amaç: Toplum kökenli akut bakteriyel sistitle (TK-ABS) toplumda oldukça sık karşılaşılmaktadır. Bu çalışmanın amacı,
Türkiye verileri temel alınarak TK-ABS tedavisinde en etkili tedavi yaklaşımını ortaya koymaktır.
Yöntem ve gereç: TK-ABS olguları ile ilgili mikrobiyolojik verilerin değerlendirildiği makaleler uluslararası ve Türkiye
veritabanları taranarak araştırıldı.
Bulgular: Türkiye’de ampirik olarak kullanılan trimetoprim-sulfametaxazol, amoksisilin klavulanat, birinci ve ikinci
kuşak sefalosporinler yeterince güvenilir değildir. Bunlar yerine fosfomisin ve nitrofurantain temel kullanımda olması
gereken antibiyotikler gibi görünmektedir. Kinolonların direnç oranlarının %20'nin üzerine çıktığı tespit edilmiştir. Diğer
yandan aminoglikozidler, üçüncü ve dördüncü kuşak sefalosporinler, piperasillin-tazobaktam bu açıdan daha güvenilir
ilaçlar olduğu görülmektedir.
Sonuç: Türkiye verileri ele alındığında, TK-ABS tedavisinde potansiyel olarak kullanılan antibiyotikler giderek etkinliğini
yitirmektedir. Toplum kökenli bu enfeksiyonlarda gerçek endikasyonlarda doğru antibiyotik kullanımı konusunda dikkatli
olunmalıdır.
Anahtar sözcükler: Toplum-kökenli, üriner, enfeksiyon, Türkiye

Received: 05.08.2009 – Accepted: 28.06.2010
1
Department of Infectious Diseases and Clinical Microbiology, Gülhane Medical Academy, Ankara - TURKEY
2
Department of Infectious Diseases and Clinical Microbiology, Kasımpaşa Military Hospital, Ankara - TURKEY
3
Department of Emergency Medicine, Urology Unit. Gülhane Medical Academy, Ankara - TURKEY
Correspondence: Ömer COŞKUN, Department of Infectious Diseases and Clinical Microbiology, Gülhane Medical Academy, Ankara - TURKEY
E-mail: coskunomer23@gmail.com

149

Cystitis in Turkey

Introduction
Urinary tract infection (UTI) is one of the most
common infectious presentations in the community
and is defined as the presence of pyuria and clinical
findings concordant with inflammation in the urinary
system (1). Nonelderly patients with dysuria,
frequency, or urgency without flank pain or fever, and
who are otherwise healthy, are not pregnant, and have
no known abnormalities of the urinary tract are
considered to have community acquired acute
bacterial cystitis (CA-ABC) (2).
According to the Turkish Statistical Institute
(Türkiye İstatistik Kurumu), UTI was the third most
common infection in Turkish medical practice
following respiratory and gastrointestinal infections
in 2004 (3). Moreover, the extensive use of
antimicrobial agents has resulted in the development
of antibiotic resistance, which has become a major
problem worldwide (4). For this reason, therapeutic
strategies should be updated due to changing
epidemiology and the aim of this paper is to put
forward a rationale based on Turkish data for
antibiotic therapy in CA-ABC.
Methods
The publications evaluating the microbiological
data obtained from CA-ABC cases were searched
through both Turkish (Pleksus) and international
(Medline) databases. The search terms were agents,
urinary-infection, community-acquired, Turkey, and
their Turkish counterparts. Only the articles
published after 2000 were included in this review.
Data analysis was done according to the design below:
1. If the publications evaluated both hospital and
community-acquired infections or isolates, the
information related to nosocomial data was
excluded.
2. The studies evaluating the results of the pediatric
population were excluded.
3. The distribution of urinary pathogens was
evaluated to delineate the potential uropathogenic
bacteria in Turkey and the median rates were
considered to provide a general understanding.
The bacteria for which the median percentage
exceeds 5% were accepted as significant
uropathogens.
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4. The median antibiotic resistance rate of a given
antibiotic was used to provide general
understanding.
5. If the study evaluated only a particular
uropathogen, this was not included for the
delineation of uropathogens, but it was only used
for antibiotic resistance pool of the particular
microorganism.
Limitations of the study
1. Local Turkish studies did not discriminate
between complicated and uncomplicated CAABCs.
2. Turkish studies have almost always focused on
laboratory data and the clinical correlations of in
vitro data are lacking in the Turkish literature. For
this reason, we combined the general knowledge
with Turkish in-vitro data on antibiotic
susceptibility.
Results
Overall 9 studies were included for pathogen
distribution in CA-ABC and 29 studies were pooled
for antibiotic susceptibility patterns. Two of the
antibiotic susceptibility studies evaluated more than
5000 isolates. In 1 study 2687 isolates, in 7 trials 10002000 strains, in 9 studies 250-1000 bacteria, in 9 trials
100-250 isolates, and in 1 study 72 strains were
assessed. Escherichia coli was the most common
pathogen, followed by Klebsiella species in CA-ABC
in Turkey. All other agents of urinary infection with
shares of less than 5% were not interpreted as
significant uropathogens. Local studies related to
pathogen distribution in CA-ABC are presented in
Table 1 and antibiotic susceptibility patterns of the
isolates are shown in Table 2.
In this study, we detected exceedingly high
resistance rates (over 20%) to ampicillin, amoxicillinclavulanic acid, trimetoprin-sulfametaksazole (SXT),
cefazolin and cefuroxime, which have been
traditionally used in the management of CA-ABC.
Fosfomycin and nitrofurantoine seem to have perfect
in-vitro efficacies on E. coli, the most frequent agent
in CA-ABC.
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Table 1. Turkish studies evaluating the pathogen distribution of CA-ABC as percentages.
References

(41)

(42)

(43)

(44)

(45)

(46)

(47)

(48)

(49)

Publication date

2001
(%)

2001
(%)

2003
(%)

2005
(%)

2006
(%)

2006
(%)

2006
(%)

2008
(%)

2008
(%)

Range
(median)

E. coli
Klebsiella spp.
Proteus spp.
Enterobacter spp.
Serratia spp.
Pseudomonas spp.
Enterococci
CNS
S. aureus
Others

70.5
6.3
0
4.4
0.6
6.3
2.5
6.3
2.5
0.6

62
16
3
6
0
7
0
0
4
2

48.8
10.7
5.1
1.4
0
4.1
5.6
5.2
5.8
13.3

90
8
1
1
0
0
0
0
0
0

80.3
17
1.3
0
0
0
0
1.3
0
0

57
5
3
8
0
0
4
12
4
7

71.5
15.5
3.3
2.3
0
3
3.5
0
0
0

66
6.4
13
0
0
2.1
9.1
0
3
0.4

58
11
4
2
0
3
7
3
1
11

48.8-90 (66)
5-17 (10.7)
0-13 (3)
0-8 (2)
0-0.6 (0)
0-7 (3)
0-9.1 (3.5)
0-12 (1.3)
0-5.8 (2.5)
0-13.3 (0.6)

*CNS; Coagulase-negative Staphylococcus. Bold numbers are the median values

Table 2. Studies evaluating the resistance rates of CA-ABC isolates in Turkey.

References

(22,43-69)

(43,45,47,50,53,57)

(43,47,53,57,70)

43,47,49,50,53,57,70)

(43,49,50,53,70)

Pathogens

E. coli (%)

Proteus spp. (%)

Enterobacter spp. (%)

Klebsiella spp. (%)

P. aeruginosa (%)

Ampicillin

37-82.4 (55.2)

7.4-72.7 (47.8)

80-100 (80.6)

79-100 (91)

85

Amx-Clav

9.8-40 (26)

12.1-30 (21)

76

6.2-64 (41.5)

Cephazolin

7-49 (28.8)

Cefuroxime

5.4-34.2 (22)

16.7-29 (23)

28-62.5 (43)

20.3-54 (42)

46

Ceftriaxone

1.6-29.6 (7)

0-18 (0)

57

4.8-36 (27.5)

73

Ceftazidime

2-9.8 (6.2)

4-6 (5)

50

5-25 (25)

0-25 (20.5)

Cefepime

1.7-13 (9.7)

4

7.5-15 (11.2)

0-13 (7.8)

19 (19)

11.7-63.3 (40.2)

43-90.9 (48.5)

20-69.7 (48.9)

15.6-48 (35.3)

31-90.6 (88)

Gentamicin

3.1-47 (11)

13-20 (16.5)

5.8-43 (24.4)

11.7-30 (17.7)

33.3-67 (37.5)

Fosfomycin

0-3 (0.6)
2.3-27 (20.5)

SXT

100

Amikacin

0.8-32 (4.5)

0-12 (4.4)

6.4-57 (31.7)

3.9-33 (19.5)

Nitrofurantoin

0.05-18 (5.3)

3.5-57 (36.3)

4.4-30 (17.2)

9.8-76 (11.6)

Ciprofloxacin

6.2-39 (18.5)

0-17 (6.7)

7.9-43 (17.1)

5.8-30 (18)

8.1-52 (22)

3.1-17 (10)

1.6

22.7

15.3-35 (22.6)

19

0-3 (1)

0-10 (4)

0-7 (0)

0-5 (0)

7-17 (13)

Pip-tazo
Imipenem

Amx-Clav= Amoxicillin-clavulanic acid; SXT= Trimetoprim-sulfametoxazol; Pip-tazo=Piperacillin-Tazobactam
Median ratio is presented in bold

151

Cystitis in Turkey

Discussion
Trimethoprim sulfamethoxazole, quinolones,
beta-lactams, nitrofurantoin, and fosfomycin have
long been the recommended antibiotic choices in CAABCs (2). In almost all cases, antimicrobial therapy is
initiated empirically before the results of urine culture
are available. The most important factors that
influence the selection of antimicrobial agents are the
probable susceptibility of the organism, ease of
administration, and the relative cost. The prevalence
of antimicrobial resistance in both community and
hospital patients with UTI are increasing and can vary
according to region (5,6). For example, the 2005-2006
resistance rates of community acquired E. coli isolates
in
England
were
ampicillin
54%,
amoxicillin/clavulanate 12%, ciprofloxacin 9%,
nitrofurantoin 5%, and trimethoprim 39% (7), and in
Spain fosfomycin 1.7%, nitrofurantoin 3.8%,
amoxicillin-clavulanic 8.1%, cefuroxime 8.9%, and
ciprofloxacin 23.9% were nonsusceptible (8). As the
problem of antimicrobial resistance became more
widespread, the use of narrow-spectrum
antimicrobial agents turned out to be less feasible and
in CA-ABCs, which have traditionally been readily
treatable, therapeutic challenges began to appear (9).
On the other hand, the costs of antibiotic resistance
are generally ignored in economic evaluations of
alternative strategies to manage infectious diseases. In
a British study, there were significantly higher
antibiotic costs for patients whose UTIs were resistant
to at least one antibiotic compared with those with
sensitive infections (10).
E. coli is by far the most frequent infecting
organism in acute UTIs. In recurrent urinary tract
infections, especially in the presence of structural
abnormalities of the urinary tract, the relative
frequency of infection caused by Proteus,
Pseudomonas, Klebsiella, and Enterobacter species
and by enterococci and staphylococci increases
greatly. More than 95% of urinary tract infections are
caused by a single bacterial strain in CA-ABC (11).
According to our data E. coli and Klebsiella species
were significant uropathogens in Turkey in CA-ABC
and various gram-positives or negatives were seen
infrequently with less than 5% ratios. Thus, the
antibiotic susceptibility patterns of these 2
microorganisms, of E. coli in particular, should be
152

taken into consideration in the management of CAABC.
In vitro resistance is expected to correlate with
clinical and bacteriologic response to therapy in most
infections. However, because most antimicrobial
agents used to treat UTls can achieve high urinary
concentrations, it may not translate into therapeutic
failure (2). McCarty et al. found 50% bacterial
eradication and 60% clinical cure rates among women
infected with a SXT resistant uropathogen treated
with the same drug (12). Evolving evidence suggests
that SXT remains optimal first-line empiric therapy
where resistance prevalence is lower than 20% (2,13)
and this threshold is extrapolated to other antibiotics
(14). It appears that half of uropathogens in Turkey
are SXT resistant and if we interpret the Turkish data
according to the results of McCarty as a model, which
shows therapeutic failures in half of the patients when
the infecting pathogen is SXT-resistant, then one
fourth of Turkish patients would not be cured
adequately. As a result, SXT should not remain the
drug of choice for empiric therapy owing to the
cumulative data in Turkey.
Fluoroquinolones are preferred as initial agents for
empiric therapy of UTI in an area where resistance is
likely to be of concern, particularly for SXT (15,16).
They have been thought to show high bacteriological
and clinical cure rates, as well as low rates of
resistance, among most common uropathogens
(17,18) Moreover, fluoroquinolones also have a
significant postantibiotic effect against gram-negative
organisms (19). However, it was shown that there are
negative impacts of ciprofloxacin resistance to shortterm outcomes of CA-ABC patients (20). In a local
Turkish study, which evaluated the fluoroquinolone
resistance trends, 2% nonsusceptibility in 1990
reached to 20% in 2001 (21). In another Turkish study,
minimum inhibitory concentration (MIC) of
fluoroquinolones in community acquired E. coli
strains were assessed between 1999 and 2002 (22).
Although MIC 50 of the isolates was not affected,
MIC 90 values increased 4-fold for ciprofloxacin and
2-fold for both ofloxacin and levofloxacin in that 3year period. Consequently, the extensive uses of
fluoroquinolones in Turkey have led to obvious
increases in resistance rates in the community. Today,
the median rates of ciprofloxacin nonsusceptibilities
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in E. coli and Klebsiella strains were 18% for both
microorganisms, and alas these drugs are also at the
edge of 20% nonsusceptibility threshold.
Ampicillin and amoxicillin had been active against
the enteric gram-negative bacteria. These antibiotics
have an identical spectrum of activity and are not
stable to beta-lactamases. Amoxicillin is better
absorbed from the intestine when administered orally
and yields higher blood and urine levels. However,
increased resistance to aminopenicillins in
community acquired UTI isolates is seen in many
parts of the world (7,23-26). Accordingly, more than
half of the community-acquired E. coli strains were
resistant to aminopenicillins in Turkey. On the other
hand, Klebsiella strains usually show intrinsic
resistance to aminopenicillins. Nevertheless, surveys
of clinical strains revealed that some isolates of
Klebsiella that carry blaSHV remain susceptible to
aminopenicillins (27). Consequently, these drugs can
no longer be used empirically in CA-ABCs in Turkey.
The resistance profile of amoxicillin clavulanate
seems to exceed the 20% threshold. The same is true
to a degree for the first and the second generation
cephalosporins. However, third and fourth generation
cephalosporins seem to be more reliable with less than
10% resistance profiles in this part of the world. In
gram-negative pathogens, beta-lactamases remain the
most important contributing factor to beta-lactam
resistance, and their increasing prevalence, as well as
their alarming evolution, seems to be directly linked
to the clinical use of novel sub-classes of beta-lactams.
Extended-spectrum beta-lactamases (ESBL) are
capable of hydrolyzing penicillins (e.g. ampicillin and
piperacillin), cephalosporins and the monobactam
aztreonam (28). In a study performed in Turkey by
Yılmaz et al. on the risk factors for ESBL production
in E. coli or K. pneumoniae isolates obtained from CAABC, the isolates that do not produce these enzymes
were all susceptible to second, third, and fourth
generation cephalosporins. Thus, ESBL production
seems to be the main mechanism in CA-ABC agents
for resistance to cephalosporins. Moreover, the
resistance profiles of aminoglycosides, SXT,
fluoroquinolones, and beta-lactams other than
carbapenems in that study were significantly higher
in ESBL producers, leading to the understanding that
the extensive use of one of these antibiotics would

decrease the efficacy of the other drugs too (29). In a
multicentric study from Spain, cure rates were 93% in
CA-ABC cystitis patients treated with amoxicillinclavulanate when the infecting agent was susceptible.
However, only 56% of the cases were cured when the
uropathogens were intermediate or full resistant and
the difference between the 2 groups was significant
(30). On the other hand, recurrences are common in
beta-lactam use in UTIs due to the fact that either
beta-lactam agents are less effective in bacteriuria
eradication or owing to increasing in vitro resistance
(31). Therefore, they are not preferred agents in the
treatment of UTIs. Beta-lactams can be preferred in
certain settings such as pregnancy or both ampicillin
and amoxicillin may still be appropriate choices when
enterococci are suspected (2).
The major drawback that led to decreased use of
aminoglycosides during the last decade was the
adverse effects. Aminoglycoside antibiotics are
equally effective as fluoroquinolones in achieving a
clinical improvement in patients with UTIs and the
discontinuation of therapy rates of these different
classes of antibiotics are similar. The present data
support the use of aminoglycosides in patients with
UTI who are not immunosuppressed, without renal
dysfunction and who are not pregnant (32), but the
most important shortcoming was that these drugs
have only parenteral formulations and this may cause
problems during administration to outpatients.
However, in certain circumstances as in therapeutic
failures, gentamicin can be recommended as an
empirical regimen in Turkey. Due to the evolving
resistance burden, however, it would be more rational
to reserve amikacin for more resistant and culture
proven pathogens.
Nitrofurantoin has been in clinical use for several
decades and is one of the oldest urinary anti-infective
agents. It is used primarily for the treatment of cystitis
since it does not attain appreciable serum levels. It is
90% renally excreted, and therefore the urine
concentration is very high, making it an effective
urinary anti-infective agent for most gram-positive
and gram-negative uropathogens (33). The drug is
well tolerated, and generally demonstrates a
consistently low level of resistance among E. coli,
gram-positive cocci, and many gram-negative species.
Nevertheless, nitrofurantoin is less effective against
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Proteus species, and some Enterobacter and Klebsiella
strains. According to Turkish data the median
resistance rate in E. coli is around 5% while one third
of Klebsiella and Proteus species seem to confer
resistance to nitrofurantoin. In one study,
nitrofurantoin was less effective than SXT when both
were given for 3 days (34), but, in a recent report, a 5day course of nitrofurantoin was found to be
equivalent to a 3-day course of SXT for clinical cure
(35). Consequently, nitrofurantoin appears to be a safe
and generally effective agent for the treatment of CAABC in Turkey, but it should be administered for a
minimum of 5 days.
Another oral drug, fosfomycin has been approved
for use as single-dose therapy for the treatment of
acute uncomplicated cystitis (2,36). Although the
drug eliminates E. coli or Enterococcus faecalis, it is not
approved for use in cystitis caused by S. saprophyticus
or for treatment of pyelonephritis. It achieves very
high concentrations in the urine and persists in the
urine for more than 24 h (37). The efficacy of
fosfomycin was also proved in a Turkish study, in
which the drug was given as 3 g once daily for 3 days.
In this study, the overall clinical and microbiological
successes were 94.3% and 78.5%, respectively (38). In
another Turkish study, 3 g of single dose fosfomycin
was equal to 3 days of ciprofloxacin treatment,
although side effects were more frequent in the
ciprofloxacin arm (39). Nonetheless, it is generally
accepted that single-dose therapy with fosfomycin was

less effective in eradicating bacteriuria than was SXT
for 10 days or ciprofloxacin for 7 days (2). Moreover,
fosfomycin was effective on all ESBL producers of CAABC with a high cure rate (30,38). Although
fosfomycin seems to be a suitable first-line medication
according to Turkish epidemiology, therapeutic
failures should be monitored.
Current management of CA-ABC is usually
empirical, without the use of a urine culture or
susceptibility testing to guide therapy. The rationale
for this approach is based on the narrow and
predictable spectrum of etiologic agents that cause
acute cystitis and their susceptibility patterns (2,40).
In vitro data show that significant uropathogens in
Turkey are fosfomycin and nitrofurantoin susceptible
and these 2 drugs may serve as baseline therapeutic
options, but caution seems to be indicated for
empirical fluoroquinolone use due to elevated
resistance profiles. If the clinician is to prefer betalactams on an empirical basis in certain situations like
pregnancy, third generation cephalosporins, or higher
beta lactam choices appear to be rational. Similarly,
aminoglycosides seem to be logical choices, although
potential side effects or the absence of oral
formulations of these drugs should be taken into
consideration. Finally, the most widely used
antibiotic, SXT, is no longer suitable in Turkey. Under
the light of Turkish data, urine culture and
susceptibility tests should be considered seriously
when therapy fails.
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